SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is facing significant volatility and negative sentiment following reports that Taiwanese authorities conducted a raid on the company's offices as part of an expanding probe into alleged unauthorized exports of high-end AI chips to China. Community discussion remains deeply polarized, with many investors debating whether the raid is a genuine escalation of regulatory risk or a repetitive, sensationalized narrative being used to force retail selling.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging on high volume and intense retail engagement as the community anticipates the final survival data from the REGAL Phase 3 trial. Traders are actively discussing the possibility of a massive short squeeze and a potential buyout, fueled by the company's high short interest and the imminent trigger of the 80th survival event.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is seeing significant price volatility and heightened community interest following a series of new military contract announcements and reported government initiatives to increase drone production capacity. Investors are actively debating the company's long-term defense backlog and integration progress against broader sector concerns regarding potential valuation corrections and competition in the tactical drone space.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is facing intense scrutiny as the market reacts to consecutive analyst downgrades and concerns over weakening consumer demand in China, fueling a polarized debate between bearish investors expecting further declines and bulls betting on a generational turnaround. Community discourse remains volatile, with active discussions focused on the upcoming earnings report, the impact of recent leadership changes, and whether the brand's iconic status can overcome current macro-economic headwinds.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is seeing high engagement as traders speculate on a potential market correction, with the community actively debating the durability of the AI-driven tech rally versus mounting geopolitical risks and macroeconomic pressure. Discussions center on technical setups, hedge positioning, and concerns over market manipulation, with participants split between anticipating a significant breakdown and frustration over the ETF's performance during index volatility.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is currently seeing significant retail and institutional interest as traders capitalize on the high volatility stemming from escalating U.S.-Iran geopolitical tensions and the market's reaction to potential Federal Reserve policy shifts. The community is heavily focused on technical setups and intraday scalping opportunities, with many discussing the risks of holding leveraged positions while debating whether recent price action signifies a healthy correction or a more sustained downturn.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is gaining investor attention following a strategic decision to discontinue internal discovery programs and close its Alabama research facility, a move aimed at prioritizing external innovation and increasing long-term capital efficiency. Community discourse is heavily focused on the potential that these operational adjustments are a deliberate step to streamline the company for a future buyout, amid ongoing speculation regarding the value of its HAE portfolio.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

The community is debating the near-term price outlook for XRP as the token faces downward pressure and approaches key support levels, leading to heated discussions about accumulation versus selling. Sentiment is split between those bracing for further volatility and dilution, and proponents who remain focused on potential regulatory catalysts and long-term utility.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors react to a quarterly earnings beat and raised full-year revenue guidance, with active community debate focused on the company's commercial execution and the potential impact of future reimbursement transitions. Discussion is heavily centered on the company's ability to maintain DefenCath adoption, the strategic value of its broader pipeline, and whether recent institutional moves signal long-term fundamental strength or continued price suppression by short sellers.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending as the company pivots from its historical 'HODL' strategy to a new Bitcoin monetization framework, allowing for asset sales to fund share buybacks and dividend payments. The community remains sharply divided, with bulls viewing the newfound capital flexibility as a strategic evolution to protect the balance sheet, while vocal bears argue the move signals a desperate shift that exposes fundamental cracks in the company's long-term Bitcoin accumulation thesis.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


Retail_Contrarian

Fara Way